MetaCap

ImmunityBio Inc. (IBRX)

NASDAQ: IBRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

6.02-0.55 (-8.37%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IBRX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.06
52-week range
1.95 – 12.43
Day range
6.00 – 6.53
Volume / Avg
10.57M / 12.97M
Beta
—

52-week range

$1.95$12.43

IBRX stock today

On Nov 20, IBRX ended the session at $6.02, shedding $0.55 (8.37%), versus the S&P 500's 3.70% decline. Shares are 51.6% below their 52-week high of $12.43, set on Feb 25, 2026 and 208.7% above the 52-week low of $1.95, in the middle of the past year's range. IBRX is up 204.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 189.4%.

ImmunityBio has posted a net loss over the last twelve months (EPS of -$1.06), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About ImmunityBio

Company profile

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Richard Gerald Adcock
Headquarters
San Diego, CA
Employees
684
IPO year
2015

Financial highlights

Full financials

In fiscal 2025, ImmunityBio generated $113.3 million in revenue, up 668.3% from fiscal 2024, its 3rd consecutive year of revenue growth. ImmunityBio reported a net loss of $351.4 million, compared with a loss of $413.6 million a year earlier. Gross margin was 99.3% (down from 100.0%) and operating margin -226.0%.

ImmunityBio annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$113.29M$14.74M$622.00K$240.00K$934.00K
Growth+668.31%+2270.58%+159.17%-74.30%+54.38%
Net income$-351.40M$-413.56M$-583.20M$-416.57M$-346.79M
EPS (diluted)$-0.38$-0.62$-1.15$-1.04$-0.89

Analyst forecast

Forecast

Consensus (4 analysts)

strong_buy

Avg. price target

$14.25+136.71%

  • Strong buy 1
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $12.00High $16.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.10 vs $-0.08
Surprise
-25.00%

IBRX news

All IBRX news

ImmunityBio peers

Health Care sector
IBRX peer companies
CompanyPrice% ChgMarket capCompare
KODKodiak Sciences Inc97.17-0.75%$6.35Bvs IBRX
IMVTImmunovant Inc.31.77-2.31%$6.57Bvs IBRX
SRRKScholar Rock Holding Corporation48.13-4.45%$5.87Bvs IBRX
TWSTTwist Bioscience Corporation103.32-7.44%$7.04Bvs IBRX
CGONCG Oncology Inc.79.47-2.97%$7.10Bvs IBRX
ADPTAdaptive Biotechnologies Corporation27.93-0.43%$4.52Bvs IBRX
PCVXVaxcyte Inc.55.39-5.09%$8.77Bvs IBRX
CRSPCRISPR Therapeutics AG39.10+0.44%$3.79Bvs IBRX

Indexes, lists and sector

ImmunityBio stock FAQ

What is ImmunityBio's stock price today?

IBRX last traded at $6.02 as of Nov 20, 4:00 PM EST, down 8.37% on the day. Prices are delayed at least 15 minutes.

Who is ImmunityBio's CEO?

Mr. Richard Gerald Adcock is the chief executive officer of ImmunityBio Inc., which has about 684 employees.

What is the IBRX 52-week high?

The 52-week high for IBRX is $12.43 and the 52-week low is $1.95. The stock is currently 51.6% below its high.

Compare IBRX